Perbak Capital Partners’s Exelixis EXEL Stock Holding History

Perbak Capital Partners’s Portfolio EXEL Stock Details EXEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,027	Closed	-$430K	–	91
2026 Q1	$430K	Buy	+10,027	New	+$431K	0.11%	213

Other funds holding EXEL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Perbak Capital Partners's EXEL Position: Q2 2026 in Review

Perbak Capital Partners sold out of Exelixis (EXEL) in Q2 2026, closing a stake of 10,027 shares — an estimated $430K sold.

Perbak Capital Partners first reported a position in EXEL in Q1 2026 and held it in 1 quarter. The position peaked at $430K in Q1 2026. 758 funds tracked by Wall St. Rank hold EXEL as of Q2 2026.

Perbak Capital Partners reported no remaining Exelixis position as of Q2 2026 after selling out during the quarter.
Perbak Capital Partners sold 10,027 Exelixis shares in Q2 2026, an estimated $430K.
Perbak Capital Partners first reported a position in Exelixis in Q1 2026 and held it in 1 quarter.
Perbak Capital Partners's Exelixis position peaked at $430K in Q1 2026.
758 funds tracked by Wall St. Rank held Exelixis as of Q2 2026.

Based on Perbak Capital Partners's 13F filing for Q2 2026.